Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session -Gastrointestinal, non-colorectal

2247 - CARRIE: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Istiratumab (MM-141) plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Date

19 Oct 2018

Session

Poster Discussion session -Gastrointestinal, non-colorectal

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Pancreatic Cancer

Presenters

Andrew Ko

Authors

A.H. Ko1, A. Cubillo2, M. Kundranda3, S.F. Zafar4, E. Meiri5, J. Bendell6, H. Alguel7, F. Rivera Herrero8, E. Ahn9, D. Watkins10, U.-. Pelzer11, V. Charu12, W. Downing13, B. Wang13, G. Kuesters13, J.M. Pipas13, S.L. Santillana13, V. Askoxylakis13

Author affiliations

  • 1 Medicine (hematology & Oncology), University of California San Francisco Cancer Center, 94143-1705 - San Francisco/US
  • 2 Medical Oncology, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 3 Gastrointestinal Medical Oncology, Medical Oncology, Banner MD Anderson Cancer Center, 85234 - Gilbert/US
  • 4 Medical Oncology, Florida Cancer Specialists, 33908 - Fort Myers/US
  • 5 Medical Oncology, Cancer Treatment Centers of America, 30265 - Newnan/US
  • 6 Gi Oncology Research, Sarah Cannon Research Institute/Tennessee Oncology, 37923 - Nashville/US
  • 7 Gastrointestinal Tumors And Inflammation Research, Rechts der Isar Hospital, 81675 - Munich/DE
  • 8 Medical Oncology, Hospital Universitario Marques de Valdecilla, 39008 - Santander/ES
  • 9 Medical Oncology And Hematology, Cancer Treatment Centers of America, 60099 - Zion/US
  • 10 Gastrointestinal Unit/medical Oncology, Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 11 Department Of Hematology, Oncology And Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 13353 - Berlin/DE
  • 12 Hematology/oncology, Pacific Cancer Medical Center, 92801 - Anaheim/US
  • 13 Clinical research, Merrimack Pharmaceuticals, Inc., MA 02139 - Cambridge/US
More

Resources

Abstract 2247

Background

High serum IGF-1 levels have been associated with more aggressive pancreatic cancer (PDAC). Pre-clinical data suggest that dual blockade of the IGF-1 and HER3 pathways has superior activity to IGF-1 blockade alone in PDCA. We tested whether istiratumab, an IGF-1R and ErbB3 bi-specific antibody, can enhance the efficacy of standard of care (SOC) chemotherapy in patients with high serum IGF-1 levels.

Methods

CARRIE was a randomized, double-blind, placebo-controlled, international Phase 2 study of nab-paclitaxel/gemcitabine alone or in combination with istiratumab in front-line metastatic PDAC. In Part 1, 10 patients were evaluated for PK and safety. In Part 2, patients with high free serum IGF-1 levels were randomized 1:1 to receive either istiratumab (2.8 g. IV Q2W) or placebo plus nab-paclitaxel/gemcitabine at the approved dose schedule. Heregulin (HRG) was tested in pre-treatment tumor samples. The co-primary endpoints were Progression Free Survival (PFS) in patients with high IGF-1 levels and in patients with both high IGF-1 levels and HRG+ tumors. Key secondary endpoints included Overall Survival (OS), Objective Response Rate (ORR) by RECIST v1.1, and adverse events (AEs) rate.

Results

A total of 317 patients were screened to enroll 88 patients (experimental arm n=43; control n=45) in Part 2. In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental vs. control arms, respectively (HR=1.88, p=0.027). In the combined high IGF-1/HRG+ subgroup (n=44), median PFS was 4.1 and 7.3 months, respectively (HR=1.39, p=0.42). Median OS and ORR for the overall population were similar between two arms (8.9 and 11.7 months, HR=1.36, p=0.22 and 39.5 vs. 51.2%, p=0.33, respectively). No significant difference in serious or Grade > 3 AEs was observed, although low-grade AEs leading to early discontinuation were higher in the experimental (39.5%) vs. control arm (24.4%).

Conclusions

Istiratumab failed to improve the efficacy of SOC chemotherapy in the front-line treatment of patients with metastatic PDAC and high IGF-1. High serum IGF-1 levels did not appear to be an adverse prognostic factor in this setting.

Clinical trial identification

Clinical trial information: NCT02399137.

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.